Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

858 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of A beta 42 in patients with Alzheimer's disease.
Hock C, Maddalena A, Raschig A, Müller-Spahn F, Eschweiler G, Hager K, Heuser I, Hampel H, Müller-Thomsen T, Oertel W, Wienrich M, Signorell A, Gonzalez-Agosti C, Nitsch RM. Hock C, et al. Among authors: oertel w. Amyloid. 2003 Mar;10(1):1-6. doi: 10.3109/13506120308995249. Amyloid. 2003. PMID: 12762134 Clinical Trial.
Treatment with the selective muscarinic agonist talsaclidine decreases cerebrospinal fluid levels of total amyloid beta-peptide in patients with Alzheimer's disease.
Hock C, Maddalena A, Heuser I, Naber D, Oertel W, von der Kammer H, Wienrich M, Raschig A, Deng M, Growdon JH, Nitsch RM. Hock C, et al. Among authors: oertel w. Ann N Y Acad Sci. 2000;920:285-91. doi: 10.1111/j.1749-6632.2000.tb06937.x. Ann N Y Acad Sci. 2000. PMID: 11193166 Clinical Trial.
Naturally occurring autoantibodies against beta-amyloid: investigating their role in transgenic animal and in vitro models of Alzheimer's disease.
Dodel R, Balakrishnan K, Keyvani K, Deuster O, Neff F, Andrei-Selmer LC, Röskam S, Stüer C, Al-Abed Y, Noelker C, Balzer-Geldsetzer M, Oertel W, Du Y, Bacher M. Dodel R, et al. Among authors: oertel w. J Neurosci. 2011 Apr 13;31(15):5847-54. doi: 10.1523/JNEUROSCI.4401-10.2011. J Neurosci. 2011. PMID: 21490226 Free PMC article.
Cognitive impairment in 873 patients with idiopathic Parkinson's disease. Results from the German Study on Epidemiology of Parkinson's Disease with Dementia (GEPAD).
Riedel O, Klotsche J, Spottke A, Deuschl G, Förstl H, Henn F, Heuser I, Oertel W, Reichmann H, Riederer P, Trenkwalder C, Dodel R, Wittchen HU. Riedel O, et al. Among authors: oertel w. J Neurol. 2008 Feb;255(2):255-64. doi: 10.1007/s00415-008-0720-2. Epub 2008 Jan 22. J Neurol. 2008. PMID: 18204803
Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.
Kang JH, Irwin DJ, Chen-Plotkin AS, Siderowf A, Caspell C, Coffey CS, Waligórska T, Taylor P, Pan S, Frasier M, Marek K, Kieburtz K, Jennings D, Simuni T, Tanner CM, Singleton A, Toga AW, Chowdhury S, Mollenhauer B, Trojanowski JQ, Shaw LM; Parkinson's Progression Markers Initiative. Kang JH, et al. JAMA Neurol. 2013 Oct;70(10):1277-87. doi: 10.1001/jamaneurol.2013.3861. JAMA Neurol. 2013. PMID: 23979011 Free PMC article.
Measuring Compounds in Exhaled Air to Detect Alzheimer's Disease and Parkinson's Disease.
Bach JP, Gold M, Mengel D, Hattesohl A, Lubbe D, Schmid S, Tackenberg B, Rieke J, Maddula S, Baumbach JI, Nell C, Boeselt T, Michelis J, Alferink J, Heneka M, Oertel W, Jessen F, Janciauskiene S, Vogelmeier C, Dodel R, Koczulla AR. Bach JP, et al. Among authors: oertel w. PLoS One. 2015 Jul 13;10(7):e0132227. doi: 10.1371/journal.pone.0132227. eCollection 2015. PLoS One. 2015. PMID: 26168044 Free PMC article.
858 results